Skip to content


  • Poster presentation
  • Open Access

Urinary cGMP concentrations after exposure to radio-contrast media in patient at risk for contrast media induced nephropathy (CIN) predicts 90-day morbidity and mortality

  • 1, 2Email author,
  • 1, 2,
  • 1, 2,
  • 1, 2,
  • 3 and
  • 3
BMC Pharmacology and Toxicology201314 (Suppl 1) :P29

  • Published:


  • Acute Renal Failure
  • Kidney Function
  • Multivariate Regression Analysis
  • Composite Endpoint
  • Coronary Angiogram


Acute renal failure after exposure to contrast media in patients at risk for CIN increases substantially 90-day mortality and morbidity. Biomarkers for outcome after CIN are missing so far.


We analyzed in a prospective study 233 patients with either diabetes or preexisting impaired kidney function getting intra-arterial contrast media (CM) for coronary angiograms. Urinary cGMP concentrations were analyzed 24 hours after exposure to intra-arterial CM in spot urine. The patients were followed for 90 day for the following events: death, need for transient or permanent dialysis, doubling of serum creatinine and unplanned re-hospitalization. 51 out of the 233 patients had such an event during the follow up period of 90 days after contrast media exposure. The urinary cGMP to creatinine ratio was significantly increased in patients having an event during the follow up period (p=0.011). We furthermore performed a multivariate regression analysis considering age, baseline kidney function before contrast media exposure and preexisting diabetes - all important risk factors for CIN. These analysis revealed that the urinary cGMP to creatinine ratio is an in dependent predictor of the occurrence of the composite endpoint: death, need for transient or permanent dialysis, doubling of serum creatinine and unplanned re-hospitalization (p=0.010; B=0.001; T=2.584; CI= 0.001 – 0.003).


The urinary cGMP to creatinineratio isan independent predictor of major advers events after contrast media exposure during a follow-up of 90 days.

Authors’ Affiliations

Institute for Nutritional Science, University of Potsdam, Potsdam, Germany
Center for Cardiovascular Research, Charité, Berlin, Germany
Bayer Pharma AG, Wuppertal, Germany


© Hocher et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.